[Combination of @entity618 with @entity205 and @entity1499 for the prophylaxes of acute graft versus XXXX in allogeneic peripheral stem cell transplantation].

@entity1 @entity870 @entity2150 @entity33 @entity3052 @entity205 @entity2098 @entity2132 @entity618 @entity1500 @entity1499 @entity1860
OBJECTIVE: To evaluate the efficacy of combination of @entity618 ( @entity2098 ) with @entity205 ( @entity870 ) and @entity1499 ( @entity1500 ) on prophylaxes of @entity2132 ( @entity2132 ) in HLA-matched allogeneic peripheral blood stem cell transplantation (allo-PBSCT). METHODS: Thirty-nine @entity1 with @entity3052 (n = 21) and @entity1860 (n = 17) and severe @entity2150 (n = 1) were treated with allo-PBSCT from HLA matched siblings (n = 36) or unrelated donors (n = 3). Twenty-six @entity1 were in @entity870 + @entity1500 group. @entity870 was given at a dosage of 2 mg.kg(-1).d(-1) by continuous intravenous injection for 24 h, since on day(-1) and injection of @entity870 was changed to oral administration of @entity870 around day 18. @entity870 was tapered by 10% per week after day + 90. @entity1500 was given at the dosage of 15 mg at day + 1, and 10 mg at day + 3, + 6 and + 11, respectively. Thirteen @entity1 were included in @entity2098 + @entity870 + @entity1500 group with the same dosage of @entity870 and @entity1500 as above but omitted at day + 11. @entity2098 of 2 g/day was added orally from day + 1 to day + 28 post transplantation. RESULTS: All @entity1 in both groups were successfully engrafted. The days of recovery of neutrophils and platelets were not significantly different between two groups (P > 0.05). The incidence of @entity2132 in @entity2098 + @entity870 + @entity1500 group (7.6%) was significantly lower than that in @entity870 / @entity1500 group (46.2%, P < 0.05). Incidence of grade II approximately IV @entity2132 in @entity2098 group was 0 while that in control group was 23.0%. The incidence of severe @entity33 was lower in @entity2098 group (15.4%) than in the control group (30.8%) (P < 0.05). CONCLUSION: The regimen of @entity2098 + @entity870 + @entity1500 for prevention of @entity2132 in allo-PBSCT is more efficient than that of @entity870 + @entity1500 , without adversely affecting the engraftment and relapse rate.
